BioLargo, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $37.1M
- Price
- $0.113
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 1.1M
About
BioLargo, Inc. pioneers the invention, development, and commercialization of sophisticated platform technologies. The company is dedicated to tackling critical environmental challenges, such as per- and polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater purification, managing industrial odors and volatile organic compounds (VOCs), enhancing air quality, and controlling infections. Backed by numerous issued patents, BioLargo maintains a robust product pipeline and extends its expertise through comprehensive environmental engineering services. Among its notable innovations are the Advanced Oxidation system, a water treatment solution generating potent oxidative and energetic iodine species; the Aqueous Electrostatic Concentrator, specifically designed for eliminating PFAS from water; CupriDyne Clean industrial products, which effectively neutralize stubborn odors and VOCs across various industrial settings; and specialized advanced wound care products. Established in 1991, BioLargo, Inc. is headquartered in Westminster, California.
Quick stats
Shares outstanding328.7M
Computed float265.7M
Float / shares80.8%
Key info
SectorBasic Materials
IndustryChemicals - Specialty
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000880242
Websitehttps://www.biolargo.com
AI Summary
AI-generated1/11
standardmixedearnings
BioLargo Reports Second Quarter 2026 Results; Revenue Up 12% Sequentially, Gross Margin Expands to 54%
BioLargo reported Q2 2026 revenue of $1.25 million, up 12% sequentially, with gross margin expanding to 54% despite a 55% year-over-year decline driven by the exit of the Pooph product line.
The company recorded a net loss of $4.0 million for the quarter, widening from $1.88 million a year ago, and ended the period with a working capital deficit of $1.27 million.
Management highlighted progress across subsidiaries, including a planned October relaunch of consumer products and the scaling of Clyra Medical's ViaCLYR wound care solution, while noting that 86% of capital raised was at the subsidiary level.
Red flags
- Net loss widened to $4.0 million in Q2 2026 from $1.88 million in Q2 2025
- Working capital deficit of $1.27 million as of June 30, 2026
- BioLargo guaranteed $3.97 million of Clyra's promissory notes